Low-dose rivaroxaban versus standard-dose antithrombotic therapy after left atrial appendage occlusion: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400080549

Enrollment

Unknown

Registered

2024-02-01

Start date

2024-02-01

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial

Interventions

Low-dose rivaroxaban anticoagulation group: Reduced dose of rivaroxaban (15/10mg/d: creatinine clearance rate > 50ml/min, 15mg/d

creatinine clearance rate = 50ml/min = 30ml/min, 10mg/d) for anticoagulation until 45 days after surgsurgery (patients who underwent AF catheter ablation combined with LAAO used it until 2 months afte

Standard-dose antithrombotic therapy : Standard dose of rivaroxaban (20/15mg/d: creatinine clearance rate > 50ml/min, 20mg/d

creatinine clearance rate = 50ml/min = 30ml/min, 15mg/d) (patients who underwent AF catheter ablation combined with LAAO used it until 2 months after operation), it was changed to DAPT (aspirin 100mg/

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Non-valvular atrial fibrillation patients aged 18 to 80 years with a life expectancy greater than 1 year 2. Left atrial appendage closure was successfully performed and Watchman left atrial appendage closure device was implanted (including the one-stop operation of LAAO and AF catheter ablation combined with LAAO) without complications 3. Sign the informed consent form

Exclusion criteria

Exclusion criteria: Severe hepatic and renal dysfunction: Alanine aminotransferase or aspartate aminotransferase levels increase more than 3 times the upper limit of normal; creatinine clearance rate < 30ml/min. Other clinical studies that have been registered and hospitalized may affect the research objectives. The investigator believes that the subject's physical condition is not suitable for participation in the study.

Design outcomes

Primary

Measure	Time frame
non-procedural ischemic stroke;non-procedural systemic embolization;Device-related thrombus;Major bleeding;	—

Secondary

Measure	Time frame
Minor bleeding;	—

Countries

China

Contacts

Public ContactFangyi Xiao

The First Affiliated Hospital of Wenzhou Medical University

harry686896@126.com+86 135 6628 6896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026